GRI Bio Announces Closing of $4.0 Million Public Offering

The gross proceeds to the Company from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, were approximately $4.0 million. The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $8.0 million. No assurance can be given that any of the Series Warrants will be exercised for cash. The Company intends to use the net proceeds from this offering for its product candidate de ...